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INTRODUCTION 
Cystinuria is an autosomal recessive disorder of amino acids
transport affecting the epithelial cells of the renal tubules and
gastrointestinal tract. It is characterized by increased urinary
excretion of cystine and the dibasic amino acids (ornithine,
lysine and arginine), and manifested by recurrent renal stones
due to the poor solubility of cystine in the urine. There are
three different types of cystinuria according to the urine phe-
notype in heterozygotes: type I (MIM220100), non-type I
(MIM600918), and mixed. In type I cystinuria, heterozygotes
have a normal pattern of amino acid excretion in the urine
(1). In non-type I cystinuria, heterozygotes have a variable
degree of hyperexcretion of cystine and diabasic amino acids.
Patients with mixed type cystinuria inherit type I and non-
type I alleles from either parent. 
Two genes responsible for cystinuria have been identified.
The first locus gene, SLC3A1, located on chromosome 2p-
16.3-21 encoding rBAT (related to b0,+ amino acid transpor-
ter), was identified to be the cause of type I cystinuria in 1994
(2). A second locus gene that is responsible for non-type I
cystinuria was mapped on chromosome 19q12-13.1. encod-
ing for b0,+AT (b0,+ amino acid transporter) by linkage anal-
ysis and later identified as SLC7A9 by International Cystin-
uria Consortium (3). At present, 79 mutations in SLC3A1
were reported and over 50 mutations in SLC7A9 have been
described so far (1). 
There have been several reports of cystinuria associated with
neurological manifestations; mental retardation, muscular
dystrophy, hypotonia and dwarfism, paroxysmal dyskinesia,
migraine, subacute combined degeneration of the spinal cord,
and cerebellar atrophy (4-6). In terms of pathogenetic corre-
lation between cystinuria and various neurological conditions,
it is still undetermined whether these two conditions share
a common pathogenesis or are coincidental. Genotypic eval-
uation of cystinuria associated with neurological manifesta-
tions has not been reported before. 
We report a case of non-type I cystinuria associated with
neurologic symptoms and identified new missence mutation
G173R in SLC7A9 gene.
CASE REPORT
A 13-yr-old boy was admitted due to increasing difficulty
in walking and clumsiness of the movement, noticed at about
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Non-Type I Cystinuria Associated with Mental retardation and Ataxia
in a Korean Boy with a New Missence Mutation(G173R) in the
SLC7A9 Gene
Cystinuria is an inherited renal and intestinal disease characterized by defective
amino acids reabsorption and cystine urolithiasis. It is unusually associated with
neurologic symptoms. Mutations in two genes, SLC3A1 and SLC7A9, have been
identified in cystinuric patients. This report presents a 13-yr-old boy with cystinuria
who manifested difficulty in walking, ataxia, and mental retardation. Somatosensory
evoked potential of posterior tibial nerve stimulation showed the central conduction
dysfunction through the posterior column of spinal cord. He was diagnosed non-type I
cystinuria by urinary amino acid analysis and oral cystine loading test. We screened
him and his family for gene mutation by direct sequencing of SLC3A1 and SLC7A9
genes. In this patient, we identified new missence mutation G173R in SLC7A9 gene. 
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5 yr of age by his mother. Birth history and early neurodevel-
opment until the age of 1 yr were unremarkable. He held his
head at 3 months, turned over at 5 months, and sat alone at
10 months of age. His neurodevelopments were delayed since
then; standing with support at 16 months, walk alone at 21
months of age. He used his first meaningful words at 2 yr of
age, make phrases at 4 yr of age, and simple sentences at 5
yr of age. At the age of 5 yr, his mother noticed that he walked
with a slow and broad-based gait, and all his movements were
weak. However, he did not sought medical advice. His dif-
ficulty in walking was slowly aggravated, and he also had a
difficulty in academic achievement recently. The patient has
one female sibling. His father died at age 40 by car accident.
There was no neurologic disorders and renal stone in his fam-
ily. On admission, physical examination revealed minor dys-
morphic features: long face, macrognathia, high arched palate,
and large ear. Neurologic examination disclosed mild higher
cortical dysfunction, dysarthria, upper limb and gait ataxia,
hyperreflexia with bilateral extensor toe signs. Motor power
and muscle tone were normal. The sensory examination dis-
closed no abnormalities except that vibration and position
sense were impaired in lower extremities. All cranial nerve
functions were intact. Optic fundi appeared normal. He had
no tremor or involuntary movement. Neuropsychological
evaluation revealed mild mental retardation on the K-WISC-
III: full-scale intelligence quotient, 62; Verbal Scale intelli-
gence quotient, 79; Performance Scale intelligence quotient;
47. Somatosensory evoked potential of posterior tibial nerve
stimulation revealed no cortical waves (P1) suggestive of cen-
tral conduction dysfunction through the posterior column of
the spinal cord. However, spine magnetic resonance imaging
(MRI) did not disclosed structural lesions in the spinal cord.
Electromyography, nerve conduction study, and brain MRI
were normal. Chromosome analysis and Fragile X mental
retardation 1 (FMR1) gene studies are normal. Routine uri-
nalysis and abdominal ultrasonography did not showed the
evidence of urolithiasis. Cerebrospinal fluid examination,
serum and cerebrospinal fluid lactate/pyruvate level, urine
organic acid analysis, and plasma amino acid analysis were
normal. Quantitative amino acid analysis of the urine disclos-
ed increased excretion of cystine (1,345 μ M/g Cr) and an excess
of the dibasic amino acids; ornithine, lysine, and arginine
(Fig. 1A). The oral cystine loading test resulted in elevation
of plasma cystine levels (Fig. 1C). He was diagnosed non-type
I cystinuria. His mother and sister were screened by quanti-
tative amino acid analysis of the urine and showed variable
degree of cystine and dibasic amino acids excretion (Fig. 1A). 
Mutation analysis of SLC3A1 and SLC7A9 genes was per-
formed on genomic DNA samples, which were extracted from
peripheral blood lymphocytes of the patient, his mother, and
his sister. Amplification of individual exons of the two genes
was performed using intronic primers obtained from the liter-
ature (7). Direct sequencing of entire coding region of SLC3A1
and SLC7A9 genes of the patient revealed both a G (normal)
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Fig. 1. Pedigree of family with patient that carry mutation in SLC7A9,
electropherograms of DNA sequencing for G173R mutation, and
the result of oral cystine load in the patient. (A) Pedigree of family
with patient; mutation in SLC7A9 and urine dibasic amino acid ex-
cretion. Urine amino acid excretion values for cystine (Cys), lysine
(Lys), arginine (Arg), and ornithine (Orn) are expressed in μ M/g
creatinine (normal range: Cys, 30-130; Lys, 150-630; Arg, 30-110;
Orn, 30-90). (B) Point mutation G173R (535G→A substitution) in
SLC7A9 gene localized in exon 5. Patient’s sequence has both G (normal) and A (mutant) at nucleotide 535, resulting in the presence of
Gly (codon GGA) and Arg (codon AGA). (C) Changes in plasma cystine level after an oral L-cystine dihydrochloride load of 0.25 mM/kg
body weight in the patient. 
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and A (mutant) at nucleotide 535 in exon 5, resulting in the
presence of a Gly (codon GGA) at amino acid position 173
and a Arg (codon AGA) in heterozygote state (Fig. 1B). We
identified the novel mutation, G173R and 6 known polymor-
phisms (Table 1). To confirm that G173R is not a polymor-
phism which could be found in normal control, we screened
this mutation in 50 unrelated healthy Korean. This mutation
was not present. The patients has only one mutation, G173R
in SLC7A9 gene, therefore we screened for SLC3A1 mutations
to ensure that no other mutations were missed. G173R was
also detected in the genomic DNA of the patient’s mother
and sister. 
DISCUSSION
Cystinuria is an inherited disorder of cystine and dibasic
amino acids; ornithine, lysine, and arginine. This disorder is
mainly expressed by the formation of cystine stones in the
urinary tract. More than 80% of patients develop their first
stone within the first 2 decades. On the other hand cystinuira
has been occasionally described in association with a various
neurological manifestations; mental retardation, muscular
dystrophy, hypotonia and dwarfism, paroxysmal dyskinesia,
migraine, subacute combined degeneration of the spinal cord,
and cerebellar atrophy (4-6). Our patient is similar to these in
that there is clinical evidence of posterior column, cortico-
spinal tract involvement, and mental retardation. 
Pathogenetic correlation between cystinuria and various
neurological conditions is still undetermined, and a relevant
explanation must be needed. If the amino acid transport sys-
tems of the brain closely resemble those of the kidney and
gastrointestinal tract, one might expect that cystinuria could
impaired brain functions (8, 9). Experimental results have
demonstrated that transport systems for entry of cystine and
cysteine into brain differ from those of kidney and intestine
(10). It is unlikely that cystinuric patients are at risk of im-
paired cerebral functions because of difference in the amino
acid transport systems of the nervous system (9). However,
Scriver et al. (4) reported that homozygous cystinuria is statis-
tically more prevalent in patients in mental hospitals than
in the general population. This finding suggest that cystinuric
patients are still at higher risk for impaired cerebral function. 
Cystinuria is currently classified into three types according
to the urinary phenotype in heterozygotes: type I (MIM22-
0100), non-type I (MIM600918), and mixed. In non-type I
heterozygotes showed a variable degree of urinary hyperex-
cretion of cystine and dibasic amino acids. Probands excret-
ing more than 1,300 μ M/g Cr are considered as phenotypi-
cally homozygote (11). This group include genetic homozy-
gotes as well as compound heterozygotes. In type I cystinuria,
there is no uptake of cystine by intestinal mucosal cells and
there is no rise in serum cystine following an oral cystine load.
In non-type I cystinuria, the intestinal transport of dibasic
amino acids is disturbed, but not abrogated. There is some
increment in plasma cystine following oral cystine load espe-
cially in patients which were previously classified as type III
cystinuria by old classification scheme (9). In this patient,
quantitative amino acid analysis disclosed increased urinary
cystine excretion (1,345 μ M/g Cr) within the range of phe-
notypic homozygote, and an excess of the dibasic amino acids;
ornithine, lysine, and arginine (Fig. 1A). The oral cystine load
resulted in increment of plasma cystine levels (Fig. 1C). His
mother and sister also showed increased excretion of cystine
and diabasic amino acids in urine (Fig. 1A), but less than those
of the patient. Therefore, patient was diagnosed as non-type
I cystinuria.
Despite the classification of the disease described above, a
new scheme based only on genetic aspects has recently been
proposed: Type A, caused by mutations in both alleles of SLC
3A1; type B, caused by mutations in both alleles of SLC7A9;
the possibility of type AB, with one mutation on each of the
above genes (1). We screened the family with patient for gene
mutation by sequencing of the SLC7A9 and SLC3A1 gene,
and identified a new missence mutation G173R in SLC7A9
gene in heterozygote state. The present search for mutations
covered the whole coding region and neighboring intron/
exon boundaries. Despite careful analysis of the SLC3A1 and
SLC7A9 genes, there are still a number of patients that lack
mutations or display only heterozygosity (1). 
Recently, two distinct recessive contiguous gene deletion
syndrome, Hypotonia-Cystinuria Syndrome and 2p21 dele-
tion syndrome, associated with type I cystinuria have been
described (12, 13). In these contiguous gene deletion syn-
dromes, various neurologic manifesations such as mental retar-
dation, hypotonia, developmental delay, neonatal seizure, facial
dysmorphism, and mitochondrial respiratory chain deficien-
cies were associated with type I cystinuria (14). This contigu-
ous gene deletion is already known to disrupt the coding re-
gion of at least 4 genes (SLC3A1, PREPL, PPM1B and C2-
orf34). Deletion of SLC3A1 gene causes cytinuria, and loss
of the other 3 genes are elucidated to contribute neurologic
manifestations in these contiguous gene deletion syndromes.
In this pedigree, patient’s mother and sister did not showed
clinical symptoms of cystinuria, but biochemical and molec-
Genetic alteration
wt, wild type.
Exon
Effect on 
coding region
Mutation Exon 5 c.535G>A G173R/wt
Polymorphism Exon 4 c.399C>T
Exon 4 c.425T>C V142A
Exon 5 c.507C>T
Exon 6 c.667C>A  L223M
Exon 6 c.687C>T
Exon 11 c.1143C>T
Table 1. Description of mutation and polymorphisms detected
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ular genetic data disclosed them as heterozygote of non-type
I cystinuria. They also did not showed neurologic symptoms
similar to those of the patient even though they had same
G173R mutation in SLC7A9 gene. Although the neurolog-
ic manifestations of the patient probably are not to be caused
by G173R mutation itself, it may be explained by uniden-
tified other genes associated with SLC7A9 gene mutation
including large gene deletion such as a contiguous gene dele-
tion syndrome which may be transmitted to the patient from
paternal side. Extensive genetic evaluation must be needed in
the patient and his father to answer this question. Unfortuna-
tely, we could not investigate candidate genes in the patient
and his father. Furthermore, we could not obtain proper clini-
cal information of his father.
In conclusion, we identified a new mutation, G173R, in
the exon 5 of SLC7A9 gene, in the patient with non-type I
cystinuria associated with neurologic manifestations which
presented as mental retardation and ataxia. 
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